This is therefore a comparing of the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation in Biomerica Inc. (NASDAQ:BMRA) and IsoRay Inc. (NYSEAMERICAN:ISR). The two are both Medical Instruments & Supplies companies that compete with one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica Inc.	5.28M	4.33	1.92M	-0.20	0.00
IsoRay Inc.	6.64M	3.90	6.62M	-0.12	0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Biomerica Inc. and IsoRay Inc.

Profitability

Table 2 provides us the return on assets, return on equity and net margins of both companies.

	Net Margins	Return on Equity	Return on Assets
Biomerica Inc.	-36.36%	-41.6%	-34.8%
IsoRay Inc.	-99.70%	-87.2%	-69.3%

Risk and Volatility

A -0.05 beta means Biomerica Inc.’s volatility is 105.00% less than Standard and Poor’s 500’s volatility. In other hand, IsoRay Inc. has beta of 1.17 which is 17.00% more volatile than Standard and Poor’s 500.

Liquidity

Biomerica Inc. has a Current Ratio of 5.2 and a Quick Ratio of 2.4. Competitively, IsoRay Inc.’s Current Ratio is 6.9 and has 6.6 Quick Ratio. IsoRay Inc.’s better ability to pay short and long-term obligations than Biomerica Inc.

Institutional & Insider Ownership

Roughly 1.8% of Biomerica Inc. shares are owned by institutional investors while 8.6% of IsoRay Inc. are owned by institutional investors. 4.4% are Biomerica Inc.’s share owned by insiders. Comparatively, IsoRay Inc. has 0.4% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Biomerica Inc.	-11.39%	-12.88%	-30.06%	-34.82%	-25.22%	-33.42%
IsoRay Inc.	-2.06%	-15.84%	-23.57%	-10.89%	-1.27%	1.43%

For the past year Biomerica Inc. has -33.42% weaker performance while IsoRay Inc. has 1.43% stronger performance.

Summary

Biomerica Inc. beats on 6 of the 10 factors IsoRay Inc.

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The companyÂ’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests. The company offers its products to hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, and physicians' offices, as well as to distributors. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

IsoRay, Inc. develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is headquartered in Richland, Washington.